SEC Form 4 · accession 0001104659-16-106272

T2 Biosystems, Inc. · TTOO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — SVP of Corporate Development

Period of report

Mar 16, 2016

Accepted (ET)

Mar 18, 2016 · 12:49 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001492674

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Mar 16, 2016	M	4,647	$1.16	A	4,647	D
Common Stock^F1	Mar 16, 2016	S	4,647	$8.00	D	0	D
Common Stock	Mar 16, 2016	M	2,941	$1.31	A	2,941	D
Common Stock^F2	Mar 16, 2016	S	2,941	$8.03	D	0	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)	$1.16	Mar 16, 2016	M	4,647	D	Feb 27, 2013	Feb 27, 2019	Common Stock	4,647	0	D
Stock Option (Right to Buy)	$1.31	Mar 16, 2016	M	2,941	D	Feb 5, 2014	Feb 5, 2020	Common Stock	2,941	0	D

F1The price reported is a weighted average price. The shares were sold in multiple transactions at per share price ranging from $8.00 to $8.04. The reporting person undertakes to provide upon request the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2The price reported is a weighted average price. The shares were sold in multiple transactions at per share price ranging from $8.00 to $8.12. The reporting person undertakes to provide upon request the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.